Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant degarelix ± apalutamide before radical prostatectomy in intermediate/high-risk prostate cancer
2016-002854-19Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- May 2017
- Modality
- Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing Degarelix + placebo with Degarelix + apalutamide (2 arms). Primary endpoint: Minimal residual disease rate. Started May 2017; status: completed.
02
Drugs
degarelixapalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2016-002854-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002854-19.